혈관과 섬유증의 평활근 및 세포외기질 조절에 대한 릴랙신의 다양한 작용기전 = Diverse Mechanisms of Relaxin's Action in the Regulation of Smooth Muscles and Extracellular Matrix of Vasculature and Fibrosis

다국어 초록 (Multilingual Abstract)

Relaxin has been demonstrated to have regulatory functions on both the smooth muscle and extracellular matrix (ECM) of blood vessels and fibrotic organs. The diverse mechanisms by which relaxin acts on small resistance arteries and fibrotic organs, including the bladder, are reviewed here. Relaxin induces vasodilation by inhibiting the contractility of vascular smooth muscles and by increasing the passive compliance of vessel walls through the reduction of ECM components, such as collagen. The primary cellular mechanism whereby relaxin induces arterial vasodilation is mediated by the endothelium-dependent production of nitric oxide (NO) through the activation of RXFP1/PI3K, Akt phosphorylation, and eNOS. In addition, relaxin triggers different alternative pathways to enhance the vasodilation of renal and mesenteric arteries. In small renal arteries, relaxin stimulates the activation of the endothelial MMPs and EtB receptors and the production of VEGF and PlGF to inhibit myogenic contractility and collagen deposition, thereby bringing about vasodilation. Conversely, in small mesenteric arteries, relaxin augments bradykinin (BK)-evoked relaxation in a time-dependent manner. Whereas the rapid enhancement of the BK-mediated relaxation is dependent on IKCa channels and subsequent EDH induction, the sustained relaxation due to BK depends on COX activation and PGI2. The anti-fibrotic effects of relaxin are mediated by inhibiting the invasion of inflammatory immune cells, the endothelial-to-mesenchymal transition (EndMT), and the differentiation and activation of myofibroblasts. Relaxin also activates the NOS/NO/cGMP/PKG-1 pathways in myofibroblasts to suppress the TGF-β1-induced activation of ERK1/2 and Smad2/3 signaling and deposition of ECM collagen.

국문 초록 (Abstract)

혈관과 섬유증 기관들의 평활근과 세포외기질에 대한 릴랙신의 조절기능이 입증되어왔다. 본 총설에서는 저항성 소동맥과 방광을 포함한 섬유증 기관들의 세포외기질에 작용하는 릴랙신의 다양한 기전들을 고찰한다. 릴랙신은 혈관 평활근육의 수축을 억제하고, 콜라겐과 같은 세포외기질의 구성성분들을 감소키켜 혈관벽의 수동적 신전성을 증가시킴으로써, 혈관확장을 유도한다. 릴랙신이 동맥의 혈관확장을 유도하는 주된 세포기전은 RXFP1/ PI3K의 활성화, Akt 인산화 및 eNOS 활성화를 통한 내피세포-의존성 산화질소의 생성에 의해 매개된다. 추가적으로, 릴랙신은 또한 다른 대체경로들을 작동하여 신장과 장간막 동맥의 혈관확장을 증가시킨다. 신장 소동맥에서, 릴랙신은 내피세포의 MMPs 및 EtB 수용체의 활성화와 VEGF 및 PlGF의 생성을 촉진하여, 평활근의 수축성과 콜라겐의 침착을 억제함으로써 혈관확장을 초래한다. 이와 달리, 장간막 소동맥에서, 릴랙신은 bradykinin (BK)-유도 이완을 시간-의존적으로 증강시킨다. BK-매개 이완의 신속 증가는 IKCa 이온통로와 뒤이은 EDH 유발에 의존하는 반면, BK에 의한 지속적 이완은 COX 활성과 PGI2에 의존한다. 릴랙신의 항섬유화 효과는 염증유발 면역세포의 침투, endothelial-to-mesenchymal transition (EndMT) 및 근섬유아세포의 분화와 활성을 억제하여 매개된다. 릴랙신은 또한 근섬유아세포 내 NOS/NO/cGMP/PKG-1 경로를 활성화하여, TGF-β1-유도 ERK1/2 및 Smad2/3 신호의 활성과 ECM 콜라겐의 침착을 억제한다.

참고문헌 (Reference)

• 1 Jeyabalan, A., "Vascular metalloproteinase-9 mediates the inhibition of myogenic reactivity in small arteries isolated from rats after short-term administration of relaxin" 148 : 189-197, 2007
• 2 Leo, C. H., "Vascular actions of relaxin : nitric oxide and beyond" 174 : 1002-1014, 2017
• 3 Casten, G. G., "Use of relaxin in the treatment of scleroderma" 166 : 319-324, 1958
• 4 Conrad, K. P., "Unveiling the vasodilatory actions and mechanisms of relaxin" 56 : 2-9, 2010
• 5 Gieseek 3rd, R. L., "Type 2 immunity in tissue repair and fibrosis" 18 : 62-76, 2018
• 6 Yue, Y., "Transforming growth factor beta(TGF-beta)mediates cardiac fibrosis and induces diabetic cardiomyopathy" 133 : 124-130, 2017
• 7 Leo, C. H., "Time-dependent activation of prostacyclin and nitric oxide pathways during continuous i.v. infusion of serelaxin (recombinant human H2 relaxin)." 173 : 1005-1017, 2016
• 8 Samuel, C. S., "The relaxin gene-knockout mouse : a model of progressive fibrosis" 1041 : 173-181, 2005
• 9 Heeg, M. H., "The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway" 68 : 96-109, 2005
• 10 Wang, C., "The anti-fibrotic actions of relaxin are mediated through a NO-sGC-cGMPdependent pathway in renal myofibroblasts in vitro and enhanced by the NO donor, diethylamine nonoate" 7 : 91-, 2016
• 11 Eser, P. O., "TGFbeta pathway inhibition in the treatment of non-small cell lung cancer" 184 : 112-130, 2018
• 12 Katz, L. H., "TGF-beta signaling in liver and gastrointestinal cancers" 379 : 166-172, 2016
• 13 Meng, X. M., "TGF-beta : the master regulator of fibrosis" 12 : 325-338, 2016
• 14 Sarwar, M., "Serelaxin-mediated signal transduction in human vascular cells : bell-shaped concentrationresponse curves reflect differential coupling to G proteins" 172 : 1005-1019, 2015
• 15 Wang, D., "Serelaxin improves cardiac and renal function in DOCA-salt hypertensive rats" 7 : 9793-, 2017
• 16 Leo, C. H., "Serelaxin : a novel therapeutic for vascular diseases" 37 : 498-507, 2016
• 17 Raleigh, J. V., "Reperfusion therapy with recombinant human relaxin-2(serelaxin)attenuates myocardial infarct size and NLRP3 inflammasome following ischemia/reperfusion injury via eNOS-dependent mechanism" 113 : 609-619, 2017
• 18 Sherwood, O. D., "Relaxin’s physiological roles and other diverse actions" 2 : 205-234, 2004
• 19 Bani-Sacchi, T., "Relaxin-induced increased coronary flow through stimulation of nitric oxide production" 116 : 1589-1594, 1995
• 20 Braddon, S. A., "Relaxin-dependent adenosine 6’, 5’-monophosphate concentration changes in the mouse pubic symphysis" 102 : 1292-1299, 1978
• 21 Ikeda, Y., "Relaxin-2 therapy reverses radiation-induced fibrosis and restores bladder function in mice" 37 : 2441-2451, 2018
• 22 Samuel, C. S., "Relaxin-1-deficient mice develop an age-related progression of renal fibrosis" 65 : 2054-2064, 2004
• 23 Dschietzig, T., "Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist : attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK–1/2 and nuclear factor-kappaB" 92 : 32-40, 2003
• 24 Evans, J. A., "Relaxin(releasin)therapy in diffuse progressive scleroderma; a preliminary report" 79 : 150-158, 1959
• 25 Meera, P., "Relaxin stimulates myometrial calcium-activated potassium channel activity via protein kinase A" 269 : C312-C317, 1995
• 26 Chow, B. S. M., "Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases : the additional involvement of iNOS" 7 : e42714-, 2012
• 27 Martin, B., "Relaxin reverses inflammatory and immune signals in aged hearts" 13 : e0190935-, 2018
• 28 Chow, B. S. M., "Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis" 86 : 75-85, 2014
• 29 Samuel, C. S., "Relaxin remodels fibrotic healing following myocardial infarction" 91 : 675-690, 2011
• 30 Debrah, D. O., "Relaxin regulates vascular wall remodeling and passive mechanical properties in mice" 111 : 260-271, 2011
• 31 Beiert, T., "Relaxin reduces susceptibility to post-infarct atrial fibrillation in mice due to anti-fibrotic and anti-inflammatory properties" 490 : 643-649, 2017
• 32 Sassoli, C., "Relaxin prevents cardiac fibroblast-myofibroblast transition via Notch-1-mediated inhibition of TGF-β/Smad3 signaling" 8 : e63896-, 2013
• 33 Unemori, E. N., "Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts" 265 : 10681-10685, 1990
• 34 Fallowfield, J. A., "Relaxin modulates human and rat hepatic myofibroblast function and ameliorates portal hypertension in vivo" 59 : 1492-1504, 2014
• 35 Samuel, C. S., "Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo" 145 : 4125-4133, 2004
• 36 Conrad, K. P., "Relaxin modifies systemic arterial resistance and compliance in conscious, nonpregnant rats" 145 : 3289-3296, 2004
• 37 Vodstrcil, L. A., "Relaxin mediates uterine artery compliance during pregnancy and increases uterine blood flow" 26 : 4035-4044, 2012
• 38 Debrah, D. O., "Relaxin is essential for systemic vasodilation and increased global arterial compliance during early pregnancy in conscious rats" 147 : 5126-5131, 2006
• 39 Novak, J., "Relaxin is essential for renal vasodilation during pregnancy in conscious rats" 107 : 1469-1475, 2001
• 40 Mookerjee, J., "Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2" 23 : 1219-1229, 2009
• 41 Nistri, S., "Relaxin inhibits lipopolysaccharide-induced adhesion of neutrophils to coronary endothelial cells by a nitric oxide-mediated mechanism" 17 : 2109-2111, 2003
• 42 Zhou, X., "Relaxin inhibits cardiac fibrosis and endothelial-mesenchymal transition via the Notch pathway" 9 : 4599-4611, 2015
• 43 McGuane, J. T., "Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide" 152 : 2786-2796, 2011
• 44 Unemori, E. N., "Relaxin induces an extracellular matrix degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo" 98 : 2739-2745, 1996
• 45 Rao, M. R., "Relaxin increases calcium efflux from rat myometrial cells in culture" 119 : 435-437, 1986
• 46 Bathgate, R. A., "Relaxin family peptides and their receptors" 93 : 405-480, 2013
• 47 Halls, M. L., "Relaxin family peptide receptors RXFP1 and RXFP2 modulate cAMP signaling by distinct mechanisms" 70 : 214-226, 2006
• 48 Samuel, C. S., "Relaxin family peptide receptor-1 protects against airway fibrosis during homeostasis but not against fibrosis associated with chronic allergic airways disease" 150 : 1495-1502, 2009
• 49 Masterson, R., "Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro" 19 : 544-552, 2004
• 50 Samuel, C. S., "Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis" 17 : 121-123, 2003
• 51 Marshall, S. A., "Relaxin deficiency attenuates pregnancy-induced adaptation of the mesenteric artery to angiotensin II in mice" 310 : R847-R857, 2016
• 52 Bennett, R. G., "Relaxin decreases the severity of established hepatic fibrosis in mice" 34 : 416-426, 2014
• 53 Garber, S. L., "Relaxin decreases renal interstitial fibrosis and slows progression of renal disease" 59 : 876-882, 2001
• 54 Masini, E., "Relaxin counteracts myocardial damage induced by ischemia-reperfusion in isolated guinea pig hearts : evidence for an involvement of nitric oxide" 138 : 4713-4720, 1997
• 55 Bani, D., "Relaxin counteracts asthma-like reaction induced by inhaled antigen in sensitized guinea pigs" 138 : 1909-1915, 1997
• 56 Kanai, A. J., "Relaxin and fibrosis : emerging targets, challenges, and future targets" 487 : 66-74, 2019
• 57 Ng, H. H., "Relaxin and extracellular matrix remodeling : mechanisms and signaling pathways" 487 : 59-65, 2019
• 58 Hewitson, T. D., "Relaxin and castration in male mice protect from, but testosterone exacerbates, age-related cardiac and renal fibrosis, whereas estrogens are an independent determinant of organ size" 153 : 188-199, 2012
• 59 Zheng, G., "Relaxin ameliorates renal fibrosis and expression of endothelial cell transition markers in rats of isoproterenol-induced heart failure" 40 : 960-966, 2017
• 60 Bani, D., "Relaxin activates the L-arginine nitric oxide pathway in vascular smooth muscle cells in culture" 31 : 1240-1247, 1998
• 61 Chen, L., "Relaxin abrogates renal interstitial fibrosis by regulating macrophage polarization via inhibition of Toll-like receptor 4 signaling" 8 : 21044-21053, 2017
• 62 강영미 ; 최윤락 ; 이환모 ; 문성환 ; 강호, "Relaxin Modulates the Expression of MMPs and TIMPs in Fibroblasts of Patients with Carpal Tunnel Syndrome" 연세대학교의과대학 58 (58): 415-422, 2017
• 63 Yoshida, T., "Protective effects of relaxin against cisplatin-induced nephrotoxicity in rats" 128 : 9-20, 2014
• 64 Pini, A., "Protection from cigarette smoke-induced lung dysfunction and damage by H2 relaxin(serelaxin)" 357 : 451-458, 2016
• 65 Novak, J., "Myogenic reactivity is reduced in small renal arteries isolated from relaxin-treated rats" 283 : R349-R355, 2002
• 66 Royce, S. G., "Mesenchymal stem cells and serelaxin synergistically abrogate established airway fibrosis in an experimental model of chronic allergic airways disease" 15 : 495-505, 2015
• 67 Lee, S. B., "Mechanistic connection between inflammation and fibrosis" 119 : S22-S26, 2010
• 68 Conrad, K. P., "Maternal vasodilation during pregnancy : emerging role of relaxin" 301 : R267-R275, 2011
• 69 Nistri, S., "Mast cell inhibition and reduced ventricular arrhythmias in a swine model of acute myocardial infarction upon therapeutic administration of relaxin" 57 (57): S7-S8, 2008
• 70 Kocan, M., "ML290 is a biased allosteric agonist at the relaxin receptor RXFP1" 7 : 2968-, 2017
• 71 Jelinic, M., "Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment" 28 : 275-287, 2014
• 72 Fisher, C., "Is the pregnancy hormone relaxin also a vasodilator peptide secreted by the heart?" 106 : 292-295, 2002
• 73 Wetzl, V., "Involvement of cyclic guanosine monophosphate-dependent protein kinase I in renal antifibrotic effects of serelaxin" 7 : 195-, 2016
• 74 Bani, D., "Inhibitory effects of relaxin on human basophils activated by stimulation of the Fc epsilon receptor. The role of nitric oxide" 2 : 1195-1204, 2002
• 75 Schinner, E., "Inhibition of the TGFβ signaling pathway by cGMP and cGMP-dependent kinase I in renal fibrosis" 7 : 550-561, 2017
• 76 Ng, H. H., "Increased superoxide production and altered nitric oxide-mediated relaxation in the aorta of young but not old male relaxin-deficient mice" 309 : H285-H296, 2015
• 77 Du, X-J., "Increased myocardial collagen and ventricular diastolic dysfunction in relaxin deficient mice : a gender-specific phenotype" 57 : 395-404, 2003
• 78 Bennet, R. G., "Inbibition of markers of hepatic stellate cell activation by the hormone relaxin" 66 : 867-874, 2003
• 79 van Drongelen, J., "Impaired vascular responses to relaxin in diet-induced overweight female rats" 112 : 962-969, 2012
• 80 Krajnc-Franken, M. A. M., "Impaired nipple development and parturition in LGR7knockout mice" 24 : 687-696, 2004
• 81 van Drongelen, J., "Impaired effect of relaxin on vasoconstrictor reactivity on spontaneous hypertensive rats" 49 : 41-48, 2013
• 82 Conrad, K. P., "G-Protein-coupled receptors as potential drug candidates in preeclampsia : targeting the relaxin/insulin-like family peptide receptor 1 for treatment and prevention" 22 : 647-664, 2016
• 83 Hisaw, F. L., "Experimental relaxation of the pubic ligament of the guinea pig" 23 : 661-663, 1926
• 84 Novak, J., "Evidence for local relaxin ligand-receptor expression and function in arteries" 20 : 2352-2362, 2006
• 85 Kerchner, L. J., "Evidence against the hypothesis that endothelial endothelin B receptor expression is regulated by relaxin and pregnancy" 146 : 2791-2797, 2005
• 86 Jeyabalan, A., "Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries" 93 : 1249-1257, 2003
• 87 Gooi, J. H., "Enhanced uterine artery stiffness in aged pregnant relaxin mutant mice is reversed with exogenous relaxin treatment" 89 : 18-, 2013
• 88 Hewitson, T. D., "Endogenous relaxin is a naturally occuring modulator of experimental renal tubulointerstitial fibrosis" 148 : 660-669, 2007
• 89 Conrad, K. P., "Emerging role of relaxin in the maternal adaptations to normal pregnancy : implications for preeclampsia" 31 : 15-32, 2011
• 90 Nishikori, K., "Effects of relaxin on rat uterine myosin light chain kinase activity and myosin light chain phosphorylation" 258 : 2468-2474, 1983
• 91 Masini, E., "Effects of relaxin on mast cells : in vitro and in vivo studies in rats and guinea pigs" 94 : 1974-1980, 1994
• 92 Conrad, K. P., "Effects of relaxin on arterial dilation, remodeling, and mechanical properties" 13 : 409-420, 2011
• 93 Huuskes, B. M., "Combination therapy of mesenchymal stem cells and serelaxin effectively attenuates renal fibrosis in obstructive nephropathy" 29 : 540-553, 2015
• 94 Zhao, L., "Collagen studies in late pregnant relaxin null mice" 63 : 697-703, 2000
• 95 Beiert, T., "Chronic lower-dose relaxin administration protects from arrhythmia in experimental myocardial infarction due to anti-inflammatory and anti-fibrotic properties" 250 : 21-28, 2018
• 96 Chen, L., "Central role of dysregulation of TGF-beta/Smad in CKD progression and potential targets of its treatment" 101 : 670-681, 2018
• 97 Wynn, T. A., "Cellular and molecular mechanisms of fibrosis" 214 : 199-210, 2008
• 98 Massicotte, G., "Blunted responses to vasoconstrictors in mesenteric vasculature but not in portal vein of spontaneously hypertensive rats treated with relaxin" 190 : 254-259, 1989
• 99 Hewitson, T. D., "Antifibrotic properties of relaxin : in vivo mechanism of action in experimental renal tubulointerstitial fibrosis" 151 : 4938-4948, 2010
• 100 Samuel, C. S., "Anti-fibrotic actions of relaxin" 174 : 962-976, 2017
• 101 Cai, J., "Anti-fibrosis effect of relaxin and spironolactone combined on isoprenaline-induced myocardial fibrosis in rats via inhibition of endothelial-mesenchymal transition" 41 : 1167-1178, 2017
• 102 Yang, J., "Angiotensin II AT(2)receptor decreases AT(1)receptor expression and function via nitric oxide/cGMP/Sp1 in renal proximal tubule cells from Wistar-Kyoto rats" 30 : 1176-1184, 2012
• 103 McGuane, J. T., "Angiogenic growth factors are new and essential players in the sustained relaxin vasodilatory pathway in rodents and humans" 57 : 1151-1160, 2011
• 104 van Drongelen, J., "Aging attenuates the vasodilator response to relaxin" 300 : H1609-H1615, 2011
• 105 Leo, C. H., "Acute intravenous injection of serelaxin(recombinant human relaxin-2)causes rapid and sustained bradykinin-mediated vasorelaxation" 3 : e000493-, 2014
• 106 Li, Y., "Acute and chronic effects of relaxin on vasoactivity, myogenic reactivity and compliance of the rat mesenteric arterial and venous vasculature" 132 : 41-46, 2005
• 107 Hsu, S. Y., "Activation of orphan receptors by the hormone relaxin" 295 : 671-674, 2002
• 108 Leo, C. H., "A vasoactive role for endogenous relaxin in mesenteric arteries of male mice" 9 : e107382-, 2014